Associated Disease Details
| Disease ID: | I14 |
| DO ID: | 9970 |
| Disease Name: | Obesity |
| Definition: | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity |
| Synonyms: | Overweight |
| Class: | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition |
| Related Drugs: | Orlistat; Phentermine; Rimonabant; Sibutramine |
| Mechanism: | Both T2DM and obesity have been independently associated with an increased risk of developing NAFLD5, and improvements in insulin sensitivity have been positively associated with histological improvements in NASH and fibrosis regression. |
| Reference (PMIDs): | 31366455 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D088 | CP-945598 | Chemical drug | DB11745 | CNR1; CB-1 antagonist | -- | Under clinical trials | Details |
| D119 | Elafibranor | Chemical drug | DB05187 | PPARA; PPARD; PPARG | Anti-inflammatory | Failed in clinical trials | Details |
| D160 | Growth Hormone | Biological drug | DB00052 | GHR ligand; PRLR ligand | -- | Under clinical trials | Details |
| D204 | Licogliflozin | Chemical drug | DB15048 | SGLT1 inhibitor; SGLT2 inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D217 | Mastiha | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D260 | Orlistat | Chemical drug | DB01083 | FASN inhibitor | Enhance lipid metabolism | Under clinical trials | Details |
| D271 | Phentermine | Chemical drug | DB00191 | MAOB antagonist; MAOA antagonist; SLC6A2 inhibitor; SLC6A3 inhibitor; SLC6A4 inhibitor; SLC6A2 stimulator; SLC6A3 stimulator | Anorexic; CNS stimulant | Under clinical trials | Details |
| D305 | Rimonabant | Chemical drug | DB06155 | CNR1 antagonist | Antialcoholic drug; CNS drug | Under clinical trials | Details |
| D327 | Semaglutide | Chemical drug | DB13928 | GLP1R agonist | Antidiabetic drug | Under clinical trials | Details |
| D333 | Sibutramine | Chemical drug | DB01105 | -- | -- | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0068 | DB00182 | approved; illicit; investigational | small molecule | Amphetamine | Indication associated | Details |
| R0098 | DB00264 | approved; investigational | small molecule | Metoprolol | Therapeutic strategy associated | Details |
| R0118 | DB00333 | approved | small molecule | Methadone | Therapeutic strategy associated | Details |
| R0140 | DB00397 | approved; vet_approved; withdrawn | small molecule | Phenylpropanolamine | Indication associated | Details |
| R0298 | DB00830 | approved; illicit | small molecule | Phenmetrazine | Indication associated | Details |
| R0313 | DB00865 | approved; illicit | small molecule | Benzphetamine | Therapeutic strategy associated | Details |
| R0339 | DB00937 | approved; illicit | small molecule | Diethylpropion | Indication associated | Details |
| R0439 | DB01191 | approved; illicit; investigational; withdrawn | small molecule | Dexfenfluramine | Therapeutic strategy associated | Details |
| R0469 | DB01255 | approved; investigational | small molecule | Lisdexamfetamine | Indication associated | Details |
| R0527 | DB01550 | experimental; illicit; withdrawn | small molecule | Fenproporex | Indication associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00003 | 35259337 | Chem Phys Lipids | New insights into NAFLD based on preclinical MRI studies. | Details |
| A00005 | 35258483 | Endocr Connect | Menopause-associated risk of cardiovascular disease. | Details |
| A00009 | 35256195 | Thromb Res | Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. | Details |
| A00012 | 35255597 | Endocrinol Metab (Seoul) | The Influence of Obesity and Metabolic Health on Vascular Health. | Details |
| A00024 | 35251356 | EFSA J | Tolerable upper intake level for dietary sugars. | Details |
| A00025 | 35251100 | Front Plant Sci | Raffinose Family Oligosaccharides: Friend or Foe for Human and Plant Health? | Details |
| A00031 | 35250588 | Front Pharmacol | Platelets in Non-alcoholic Fatty Liver Disease. | Details |
| A00032 | 35250014 | Ultrasound Q | Clinical Feasibility of Shear Wave Dispersion Slope for Noninvasive Diagnosis of Nonalcoholic Steatohepatitis in Patients With Morbid Obesity: Preliminary Results Using US Shear Wave Elastography. | Details |
| A00037 | 35248654 | Diabetes Res Clin Pract | Metabolic determinants of NAFLD in adults with type 1 diabetes. | Details |
| A00038 | 35248539 | Gastroenterology | NAFLD and the Gut-Liver Axis: Exploring an Undernutrition Perspective. | Details |
| A00039 | 35247883 | Cancer Epidemiol Biomarkers Prev | Cancer epidemiology in Hispanic populations: what have we learned and where do we need to make progress? | Details |
| A00041 | 35247611 | Mol Metab | Serum Amyloid A1 Exacerbates Hepatic Steatosis via TLR4 Mediated NF-κB Signaling Pathway. | Details |
| A00045 | 35245436 | Mol Cell | Amelioration of hepatic steatosis by dietary essential amino acid-induced ubiquitination. | Details |
| A00058 | 35238782 | Turk J Gastroenterol | Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting. | Details |
| A00059 | 35238641 | Proc Natl Acad Sci U S A | Disruption of the circadian clock component BMAL1 elicits an endocrine adaption impacting on insulin sensitivity and liver disease. | Details |
| A00069 | 35232986 | Sci Rep | Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. | Details |
| A00074 | 35230042 | Swiss Med Wkly | Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis. | Details |
| A00075 | 35229847 | Food Funct | N-Acetylcysteine alleviates high fat diet-induced hepatic steatosis and liver injury via regulating the intestinal microecology in mice. | Details |
| A00076 | 35229334 | Aliment Pharmacol Ther | Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study. | Details |
| A00077 | 35229329 | Hepatology | Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis. | Details |